Vijaya Diagnostic Centre Limited has informed the Exchange regarding Appointment of Mr. Lanka Sai Srinivas as Chief Technology Officer of the company w.e.f. May 12, 2025.
VIJAYA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Vijaya Diagnostic Centre's board, meeting on May 12, 2025, approved audited standalone and consolidated results for Q4 and FY25, with statutory auditors issuing an unmodified (clean) opinion. The board recommended a final dividend of ₹2 per share (200% on face value of ₹1), subject to shareholder approval. Mr. S. Ramachandra Reddy, currently General Manager – Finance, was appointed as Interim Chief Financial Officer and Key Managerial Personnel, while Mr. Lanka Sai Srinivas (ex-UnitedHealth Group, Wipro) was appointed as Chief Technology Officer. M/s. Santhosh & Associates were re-appointed as Cost Auditors for FY26. Additionally, 1,91,150 ESOPs were granted to employees at ₹815 per option under the VDCL ESOP Plan 2018.
The clean audit, healthy dividend, and high-profile technology hire (CTO with global healthcare-IT experience) suggest a stable, growth-oriented stance and a push towards digital health initiatives. The 'interim' tag on the new CFO may indicate the company is still finalising a permanent finance chief, which investors may want to track.